Organo-platinum complexes of the following formula having excellent antitumor actions: ##STR1## X and Y each or taken together is a mono- or bi-functional ligand selected from the group consisting of halogeno, nitrato, sulfonato, monocarboxylato (mono-functional), sulfato, and dicarboxylato (bi-functional); and each of n and m is an integer of 1 or 2.

Description

17 parts

›This invention relates to antitumor agents. More particularly…

This invention relates to antitumor agents. More particularly, this invention relates to organo-platinum complexes having potent antitumor actions.

›BACKGROUND OF THE INVENTION

It has been known that some kinds of platinum complexes have antitumor actions; particularly, cisplatin [cisdiamminedichloroplatinum(II)] has been used clinically in treatment of malignancy, for example, disseminated testicular and ovarian carcinoma. Cisplatin, however, has serious side effects such as renal toxicity, myelosuppression, and ototoxicity. Recently, the occurence of malignancy and death rate owing thereto are on the increase, and it is desirable to develop antitumor agents of which the activity is strong but less toxic. In order to achieve the above purpose, chemical modification of platinum complexes has been attempted extensively. Representatives of the platinum complexes disclosed in literatures are malonato (1,2-diaminocyclohexane)platinum(II)[Japanese Unexamined Patent Publication No. 53-31648], sulfato (1,2-diaminocyclohexane)platinum(II)[Japanese Unexamined Patent Publication No. 54-44620], and the like.

›DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention are represented by the following formula: ##STR2##

(wherein X and Y each or taken together is a mono- or bi-functional ligand selected from the group consisting of halogeno, nitrato, sulfonato, monocarboxylato, (mono-functional), sulfato, and dicarboxylato (bi-functional);

and each of n and m is an integer of 1 or 2)

In the above definition, the halogeno means chloro, bromo, iodo, and the like, preferably chloro. Sulfonato includes C 1 to C 5 alkanesulfonato and C 6 to C 8 arylsulfonato. Representatives of the C 1 to C 5 alkanesulfonatoes are methanesulfonato, ethanesulfonato, propanesulfonato, isopropanesulfonato, butanesulfonato, isobutanesulfonato, sec-butanesulfonato, t-butanesulfonato, pentanesulfonato, and the like. Representative of the C 6 to C 8 arylsulfonatoes are benzenesulfonato, toluenesulfonato, xylenesulfonato, and the like. Monocarboxylato means saturated or unsaturated C 1 to C 7 monocarboxylato, including formato, acetato, propionato, butyrato, isobutyrato, valerato, acrylato, propionato, methacrylato, crotonato, isocrotonato, and the like. Preferable monocarboxylato is C 2 to C 6 monocarboxylato, preferably acetato. Dicarboxylato means saturated or unsaturated C 2 to C 10 dicarboxylato, including oxalato, malonato, succinato, maleato, fumarato, phthalato, hemimellitato, and the like, preferably, oxalato, malonato, or hemimellitato. The above monocarboxylato and dicarboxylato may optionally be substituted by halogen or hydroxy as exemplified by chloroacetato, gluconato, glucuronato, and the like, and these are also included within the scope of this invention.

In the above formula [I], when n differs from m, the configuration of the aminoes on the bicyclic structure is exocis or trans.

Representatives of the compounds [I] are as follows:

(1) dichloro[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(2) dinitrato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(3) sulfato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(4) malonato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(5) bis(chloroacetato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(6) hemimellitato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(7) oxalato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(8) bis(glycolato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(9) bis(glucuronato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II);

(10) dichloro[exo,cis-2,3-diaminobicyclo(2.2.2)octane]platinum(II); and

(11) bis(gluconato)[exo,cis-2,3-diaminobicyclo(2.2.2)octane]platinum(II).

›PREPARATION

The compounds [I] of this invention are readily prepared from the compounds of the formula [II] in the well-known conventional manner. ##STR3## (wherein n and m are the same as mentioned above)

(1) In the case of X and Y each being halogen:

The compounds [II] are reacted with alkali metal salts of tetrahalogenoplatinate(II) to give the compounds [Ia] (X and Y each is halogen in [I]). It is preferred to employ the potassium salts as the alkali metal salts of tetrahalogenoplatinate(II). This reaction proceeds in weak alkaline conditions and is preferably carried out in the presence of sodium hydrogen-carbonate. It ordinarily takes 5 to 10 hours to complete this reaction.

(2) In the case of X and/or Y being nitrato:

The compounds [Ia] are reacted with silver nitrate in an aqueous medium to give the compounds [I] wherein X and/or Y are nitrato. When one molar equivalent of silver nitrate is employed to the compounds [Ia], the compounds [Ib] (in [I] either X or Y is nitrato) are given, and when two molar equivalents of silver nitrate is employed, the compounds [Ic] (in [I] both of X and Y are nitrato) are given. This reaction is carried out under protection from light and completed within a period of 2 to 5 days.

(3) In the case of X and/or Y being sulfonato:

The compounds [Ia] are reacted with silver sulfonate, for example, silver methanesulfonate and silver benzenesulfonate to give the compounds [I] wherein X and/or Y are sulfonato. When one molar equivalent of silver sulfonate is employed to the compounds [Ia], the compounds [Id] (in [I] either X or Y is sulfonato) are given, and when two molar equivalents of silver sulfonate is employed, the compounds [Ie] (in [I] both of X and Y are sulfonato) are given.

(4) In the case of X and Y taken together being sulfato:

The compounds [Ia] are reacted with silver sulfate to give the compounds [If] (in [I] X and Y taken together is sulfato). It is preferred to effect this reaction at room temperature under protection from light, and the reaction is completed within a period of 1 to 3 days.

(5) In the case of either X or Y being nitrato and the other being monocarboxylato:

The compounds [Ic] are reacted with alkali metal salts of monocarboxylic acid to give the compounds [Ig] (in [I] either X or Y is nitrato and the other is monocarboxylato). It is preferred to one molar equivalent of alkali metal salts of monocarboxylic acid to the compounds [Ic].

(6) In the case of X and Y each or taken together being monocarboxylato or dicarboxylato:

The compounds [Ic] are reacted with monocarboxylic acids, dicarboxylic acids, or the alkali metal salts thereof in water to give the compounds [Ih] (in [I] X and Y each is monocarboxylato, or X and Y taken together represent dicarboxylato). This reaction is carried out under cooling or heating and ordinarily completed within a period of several ten minutes to several days, which time depends on the species of carboxylic acids used, and variation and number of the substituents.

The above starting compounds [II] are readily prepared from the compounds of the formula [III] shown below according to the manner described in Journal of the American Chemical Society, 89, 3005 (1967). ##STR4## (wherein n and m are the same as mentioned above)

The compounds [III] are well-known compounds, among which the compounds [III] (m=n=1) have been disclosed in Tetrahedron Letters 1968, 2789, the compounds [III] (m=2 and n=1, or m=1 and n=2) are commercially available as 2-norbornene, and the compounds [III] (m=n=2) have been disclosed in Journal of the American Chemical Society, 76, 5396 (1954).

›EFFECT

The compounds [I] of this invention have potent antitumor actions. For example, the activities of representative compounds [I] of this invention are shown below.

(Test Method)

Leukemia L 1210 ascites cells (10 5 cells) in mouse were intraperitoneally inoculated to BDF 1 mice. On the next day, the predetermined amount of the test compounds shown below was administered. Eight to ten mice were employed in a control group, and four to seven mice were employed in a test group.

(Evaluation of the effect)

From the average survival days in the test group and those of the control group, the increase of lifespan (ILS) was calculated according to the following expression. ##EQU1##

(Test compounds)

(1) dichloro[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(2) dinitrato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(3) sulfato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(4) oxalato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(5) malonato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(6) bis(glucuronato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II)

(Comparative compounds)

(7) dichloro(cis-diamine)platinum(II)

(8) dichloro(1,2-diaminocyclohexane)platinum(II)

______________________________________

(Result)

Numbers of

›Test Dosage Numbers of survivors

Compound

(mg/kg) mice employed

›ILS (%)

over 30 days

______________________________________

(1) 0 × 1

1 × 1

7 25

2 × 1

7 51

5 × 1

7 >126 2

10 × 1

7 >143 3

20 × 1

7 -21

(2) 0 × 1

1 × 1

7 32

2 × 1

7 51

5 × 1

7 80

10 × 1

7 >151 4

20 × 1

7 -18

(3) 0 × 1

1 × 1

7 21

2 × 1

7 31

5 × 1

7 48

10 × 1

7 >221 5

20 × 1

7 -35

(4) 0 × 1

1 × 1

7 3

2 × 1

7 13

5 × 1

7 > 54 1

10 × 1

7 >79 1

20 × 1

7 >149 4

(5) 0 × 1

5 × 1

7 16

10 × 1

7 20

20 × 1

7 31

50 × 1

5 >84 1

100 × 1

7 -18

(6) 0 × 1

1 × 1

7 4

2 × 1

7 17

5 × 1

7 27

10 × 1

7 >67 1

20 × 1

7 >126 2

50 × 1

7 >43 1

(7) 0 × 1

1 × 1

7 9

2 × 1

7 11

5 × 1

7 29

10 × 1

7 >84 1

20 × 1

4 -26

(8) 0 × 1

1 × 1

7 15

2 × 1

7 20

5 × 1

7 >67 1

10 × 1

7 >129 2

20 × 1

7 -7

______________________________________

As seen from the above table, the compounds [I] of this invention have potent antitumor actions.

›HOW TO USE

The compounds [I] of this invention can be administered parenterally to humans or animals in treatment of various kinds of malignancy. In using, the compounds [I] may be dissolved or suspended in a suitable solvent for injection (e.g. distilled water for injection, isotonic sodium chloride solution, ethanol, glycerin, propylene glycol, oleave oil, peanut oil), and administered intravenously, intramuscularly, or subcutaneously. In preparations for injection, the compounds [I] may be contained in ampoules in a form of solution or suspension; alternatively, it is appropriate to keep the compounds [I] in ampoules or vials in a form of crystals, powder, microcrystals, lyophilizate, and the like and to dissolve or suspend immediately before using. If necessary, stabilizing agents may be added.

When used in treatment of tumors, the compounds [I] may be administered parenterally to an adult at a single or divided doses of 1 to 100 mg 1 to 3 times a day. But it is appropriate to optionally increase or decrease the dosage according to the age, condition, or anamnesis of patients.

The following examples are provided to further illustrate this invention.

›Examples9

›EXAMPLE 1

Dichloro[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR5##

To a solution of diacetato exo,cis-2,3-diaminobicyclo(2.2.1)heptane 1 (300 mg; 1.22 mmoles) in water (3 ml) are added a solution of potassium tetrachloroplatinate(II) (468 mg; 1.23 mmoles) in water (6 ml) and then solid sodium hydrogencarbonate (206 mg; 2.45 mmoles), and the mixture is shaken, by which carbon dioxide is vigorously generated. After subsidence of carbon dioxide evolution, the reaction mixture is stirred at room temperature for 8 hours. The resulting solid is collected by filtration, washed with water, acetone, and then ether, and dried under reduced pressure to give the title compound 2 (303 mg) as pale yellowish green crystals (first crop). The mother liquor is allowed to stand overnight to give an additional crop of the title compound 2 (49 mg) as yellow crystals (second crop).

Total yield 352 mg (74%)

mp. >300° C.

Elemental Analysis:

Calcd (for C 7 H 14 N 2 PtCl 2 )(%): C, 21.44; H, 3.60; N, 7.14; Cl, 18.08.

Found (%): C, 21.40; H, 3.50; N, 6.94; Cl, 18.16. IR: ν max Nujol 3205, 3110 (--NH 2 ) cm -1 .

›EXAMPLE 2

Dinitrato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR6##

To a suspension of Compound 2 (392 mg; 1 mmole) in water (35 ml) is added silver nitrate (340 mg; 2 mmoles), and the reaction vessel is wrapped in a sheet of aluminum foil in order that the reaction mixture is shielded from light. The mixture is stirred for 3 days, and the resulting colorless precipitate (silver chloride) is removed by filtration. The excess amount of silver nitrate remaining in the filtrate is decomposed with 0.5% aqueous solution of potassium chloride, which is added to the filtrate until no turbidity produced. The filtrate is evaporated to dryness with a rotary evaporator, and the resulting residue is dried at nearly 55° C. under reduced pressure to give the title compound 3 (384 mg) in 86% yield.

mp. about 200° C. (decomposition)

Elemental Analysis:

Calcd (for C 7 H 14 N 4 O 6 Pt)(%) C, 18.88; H, 3.17; N, 12.58.

Found (%) C, 18.32; H, 3.24; N, 12.32. IR: ν max Nujol 3240, 3150 (--NH 2 ), 1466, 1274 (--NO 3 ) cm -1 .

›EXAMPLE 3

Sulfato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR7##

To a suspension of Compound 2 (275 mg; 0.7 mmole) in water (30 ml) is added silver sulfate (218 mg; 0.7 mmole), and the mixture is stirred at room temperature for 2 days under protection from light, and then worked up in the same manner as in Example 2 to give the title compound 4 (260 mg) as an yellow material in 80% yield.

mp. about 230° C. (decomposition)

Elemental Analysis:

Calcd (for C 7 H 14 N 2 O 4 SPt)(%): C, 20.15; H, 3.38; N, 6.71; S, 7.68.

Found (%): C, 18.14; H, 3.67; N, 6.30; S, 7.61. IR: ν max Nujol ˜3180, ˜3080 (--NH 2 ), 1110, 1023, 940 (--SO 4 ) cm -1 .

›EXAMPLE 4

Malonato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR8##

Compound 3 (400 mg; 0.9 mmole) is dissolved in water (20 ml) under heating at 95° C. A solution of sodium malonate monohydrate (150 mg; 0.9 mmole) in water (3 ml) is added thereto, and the mixture is allowed to stand at room temperature for 10 to 20 minutes to yield colorless crystals as precipitates. The reaction mixture is cooled with ice for nearly complete crystallization. The resulting colorless crystals are collected by filtration to give the title compound 5 (287 mg) (first crop). The mother liquor is further concentrated to about 3 ml and allowed to stand overnight to give an additional crop of the title compound 5 (38 mg) (second crop).

Total yield: 325 mg (85%)

mp. about 240° C. (decomposition)

Elemental Analysis:

Calcd (for C 10 H 16 N 2 O 4 Pt)(%): C, 28.37; H, 3.81; N, 6.62.

Found (%): C, 27.78; H, 3.71; N, 6.66. IR: ν max Nujol 3175, 3115 (--NH 2 ), 1662, 1623 (--C═O) cm -1 .

›EXAMPLE 5

Bis(chloroacetato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR9##

Compound 3 (60 mg; 0.135 mmole) is dissolved in water (3 ml) under heating, and the resultant solution is cooled to room temperature, mixed with chloroacetic acid (86 mg; 0.9 mmole), and allowed to stand in a refrigerator for 3 days. The separated crystals are collected by decantation, washed with a small amount of cold water, and dried under reduced pressure to give the title compound 6 (24 mg) containing water of crystallization (35% yield). This is repeatedly recrystallized from methylene chloride-hexane in order that the water of crystallization may be removed.

mp. 153°-156° C. (decomposition)

Elemental Analysis:

Calcd (for C 11 H 18 N 2 O 4 Cl 2 Pt)(%): C, 25.99; H, 3.57; N, 5.51.

Found (%): C, 25.48; H, 3.54; N, 5.57. IR: ν max Nujol 3195, 3100 (--NH 2 ), 1621 cm -1 .

›EXAMPLE 6

Hemimellitato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR10##

Compound 3 (48 mg; 0.108 mmole) and hemimellitic acid (22.7 mg; 0.108 mmole) are dissolved in water (1.2 ml) under heating, and the resultant solution is allowed to stand at room temperature. After 10 to 15 minutes, the colorless solid is precipitated. After 5 hours, the precipitate is collected by decantation and washed twice with a small amount of water to give the title compound 7 (10 mg) in 17% yield.

mp. about 200° C. (decomposition)

Elemental Analysis

Calcd (for C 16 H 18 N 2 O 6 Pt)(%): C, 36.30; H, 3.43; N, 5.29.

Found (%): C, 32.84; H, 3.60; N, 5.54. IR: ν max Nujol ˜3400 (--OH), ˜3200, ˜3090 (--NH 2 ), 1710, 1603, 1576 (--C═O) cm -1 .

›EXAMPLE 7

Oxalato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR11##

To a solution of Compound 3 (178 mg; 0.4 mmole) dissolved in water (5 ml) under heating is added a solution of sodium oxalate (54 mg; 0.4 mmole) in water (5 ml). The mixture is allowed to stand at room temperature and the precipitated crystals are collected by filtration to give the title compound 8 (122 mg) in 75% yield.

mp. 290°-295° C. (decomposition)

Elemental Analysis:

Calcd (for C 9 H 14 N 2 O 4 Pt)(%): C, 26.41; H, 3.45; N, 6.84.

Found (%): C, 26.35; H, 3.55; N, 6.75. IR: ν max Nujol 3210, 3110 (--NH 2 ), 1695, 1664 (--C═O) cm -1 .

›EXAMPLE 8

Bis(glycolato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR12##

Compound 3 (91 mg; 0.2 mmole) and sodium glycolate (39 mg; 0.4 mmole) are dissolved in water (6 ml) under heating, and the resultant solution is heated at 70° C. for 6 hours. Most of the solvent is evaporated under reduced pressure and the residue is mixed with a large amount of alcohol. The resultant colorless precipitate is collected by filtration and dried under reduced pressure to give the title compound 9 (31 mg) in 33% yield.

mp. 210°-215° C. (decomposition)

IR: ν max Nujol 3210, 3130 (--NH 2 ), 1618 (--C═O) cm -1 .

›EXAMPLE 9

Bis(glucuronato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II) ##STR13##

To a solution of Compound 3 (437 mg; 0.982 mmole) dissolved in water (40 ml) under heating is added sodium D-glucuronate monohydrate (468 mg; 2.00 mmoles), and the mixture is allowed to stand at room temperature for 30 minutes and evaporated to dryness with a rotary evaporator. The residue is washed with hot anhydrous ethanol (about 40 ml), dissolved in methanol, and concentrated, and the precipitated colorless solid is collected by filtration to give the title compound 10 (650 mg) in 94% yield.

mp. 155° C. (decomposition)

Elemental Analysis:

Calcd (for C 19 H 32 N 2 O 14 Pt)(%): C, 32.25; H, 4.56; N, 3.96.

Found (%): C, 29.32; H, 4.86; N, 3.95. IR: ν max Nujol 3300 (--OH), 3219, 3114 (--NH 2 ), 1620 (--C═O) cm -1 .

1 of 17 part labels are ours — the grant heads the rest

Claims

19 · 1 independent · depth 2

19 granted claims

›1.independentAn organo-platinum complex of the formula: ##STR14## wherein X and Y each or taken together is a mono- or bi-functional ligand selected from the group…+18

›2.↳ 1An organo-platinum complex claimed in claim 1, wherein either n or m is an integer of 1 and the other is an integer of 2.d2

›3.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y each is halogeno.d2

›4.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y each is nitrato.d2

›5.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y each is chloroacetato.d2

›6.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y each is glycolato.d2

›7.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y each is glucuronato.d2

›8.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y taken together is sulfato.d2

›9.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y taken together is oxalato.d2

›10.↳ 1An organo-platinum complex claimed in claim 1, wherein X and Y taken together is malonato.d2

›11.↳ 1An organo-platinum complex claimed in claim 1, namely dichloro[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›12.↳ 1An organo-platinum compex claimed in claim 1, namely dinitrato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›13.↳ 1An organo-platinum complex, claimed in claim 1, namely sulfato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›14.↳ 1An organo-platinum complex, claimed in claim 1, namely malonato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›15.↳ 1An organo-platinum complex, claimed in claim 1, namely bis(chloroacetato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›16.↳ 1An organo-platinum complex, claimed in claim 1, namely hemimellitato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›17.↳ 1An organo-platinum complex, claimed in claim 1, namely oxalato[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›18.↳ 1An organo-platinum complex, claimed in claim 1, namely bis(glycolato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

›19.↳ 1An organo-platinum complex, claimed in claim 1, namely bis(glucuronato)[exo,cis-2,3-diaminobicyclo(2.2.1)heptane]platinum(II).d2

Classifications

11 codes

IPC · International Patent Classification

Section A — Human necessities

A61P35/00
A61K31/28
A61K31/282

Section C — Chemistry; metallurgy

C07F15/00
C07C59/06
C07C53/16
C07C63/307
C07C55/07
C07C55/08

USPC · US Patent Classification

260/429.R424/287

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

1.6 y

595 days filing → grant

Office actions

on the grant's record

Examiner

Helen M. S. Sneed

art unit 117 · TC 1100

Law firm

Law firm · Log in to unlock

Citations: 12 back · 38 forward

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Worldwide family

6 members · 6 offices

this patentIP5 & PCTother officessolid = grantedhover for detail · click to open

Members

DOCDB simple family 13082118

Offices

US · JP

Granted

1 of 6

grant date present

Non-English titles

shown as filed, never translated

›IP5 & PCT — 2 members

Office	Publication	Kind	Published	Filed	Status	Title
USthis patent	US-4359425-A	A	16 Nov 1982	31 Mar 1981	granted	Organo-platinum complex
JP	JP-S56154493-A	A	30 Nov 1981	30 Apr 1980	published	Novel platinum complex

›Other offices — 4 members

Office	Publication	Kind	Published	Filed	Status	Title
DE	DE-3117216-A1	A1	4 Mar 1982	30 Apr 1981	published	Organoplatinkomplexe und ihre verwendung bei der bekaempfung von tumorende
FR	FR-2481696-A1	A1	6 Nov 1981	21 Apr 1981	published	Complexes d'organoplatine a actions antitumeursfr
GB	GB-2074567-A	A	4 Nov 1981	3 Apr 1981	published	Platinum-amine complexes
IT	IT-8167551-A0	A0	23 Apr 1981	23 Apr 1981	published	Complesso dell organo platino parti colarmente utile come agente antitumoraleit

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.